PIK3CA and breast cancer: Thus, consistent with studies emphasizing a role for PDK1 in promoting breast cancer malignancy23, our predictions indicate that PDK1 is also a prominent target for the treatment of resistant disease in ER+ breast cancers with PIK3CA mutations.